CDMO Kindeva Drug Delivery, which specializes in inhalation, intradermal, and transdermal drug delivery, has announced that it will merge with fellow Altaris Capital Partners company Meridian Medical Technologies, which specializes in autoinjectors. Altaris acquired Kindeva (formerly 3M Drug Delivery Systems) from 3M in 2020 and acquired Meridian from Pfizer in 2021. The combined CDMO will be led by current Meridian CEO Milton Boyer.
Kindeva offers development and manufacturing services for DPIs, SMIs, nebulized products, and pulmonary and nasal MDIs. The company has recently been investing in capabilities for developing and manufacturing lower-GWP MDIs, and earlier this year, announced its acquisition of inhaled drug CRO iPharma Labs.
Boyer commented, “We are incredibly excited about the opportunities that will result from the combination of two companies with deep roots in complex drug delivery. The integrated, complementary offerings of Kindeva and Meridian create a CDMO with a broad portfolio of capabilities and proprietary technology platforms across multiple drug delivery formats, enabling us to serve customers and communities across multiple large and growing end markets.”
Read the Kindeva Drug Delivery press release.
